SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-10-20
- Last Posted Date
- 2023-06-09
- Lead Sponsor
- Suven Life Sciences Limited
- Target Recruit Count
- 564
- Registration Number
- NCT02580305
- Locations
- 🇺🇸
Senior Clinical Trials, Inc., Laguna Hills, California, United States
🇺🇸Emerald Coast Center for Neurological Disorders, Pensacola, Florida, United States
🇺🇸Neurological Associates of Albany, PC, Albany, New York, United States
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-D4010 in Healthy Subjects
- First Posted Date
- 2015-10-14
- Last Posted Date
- 2016-06-06
- Lead Sponsor
- Suven Life Sciences Limited
- Target Recruit Count
- 64
- Registration Number
- NCT02575482
- Locations
- 🇺🇸
PRA Health Sciences, Lenexa, Kansas, United States
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-G3031 in Healthy Subjects
- First Posted Date
- 2015-01-19
- Last Posted Date
- 2016-10-14
- Lead Sponsor
- Suven Life Sciences Limited
- Target Recruit Count
- 64
- Registration Number
- NCT02342041
- Locations
- 🇺🇸
Quintiles, Overland Park, Kansas, United States
© Copyright 2024. All Rights Reserved by MedPath